¼¼°èÀÇ ±â´ÉÀû ³»½Ã°æ ºÎºñ°­ ¼ö¼ú ½ÃÀå
Functional Endoscopic Sinus Surgery
»óǰÄÚµå : 1757602
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 359 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,009,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,027,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ±â´ÉÀû ³»½Ã°æ ºÎºñ°­ ¼ö¼ú ½ÃÀåÀº 2030³â±îÁö 18¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 12¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ±â´ÉÀû ³»½Ã°æ ºÎºñ°­ ¼ö¼ú ½ÃÀåÀº 2024-2030³â¿¡ CAGR 5.9%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 18¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ »ó¾Ç ½Ã¼úÀº CAGR 4.9%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á±îÁö 11¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. »ç°ñ ½Ã¼ú ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 7.7%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 3¾ï 3,900¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 9.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ±â´ÉÀû ³»½Ã°æ ºÎºñ°­ ¼ö¼ú ½ÃÀåÀº 2024³â¿¡ 3¾ï 3,900¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2024-2030³âÀÇ ºÐ¼® ±â°£¿¡ CAGR 9.2%·Î ÃßÀÌÇϸç, 2030³â¿¡´Â 3¾ï 5,370¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 3.0%¿Í 5.8%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ "±â´ÉÀû ³»½Ã°æ ºÎºñ°­ ¼ö¼ú(FESS)" ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

FESS°¡ ¸¸¼º ºÎºñµ¿ Áúȯ¿¡ ´ëÇÑ ¹Ù¶÷Á÷ÇÑ Á¢±Ù¹ýÀÌ µÇ°í ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

±â´ÉÀû ³»½Ã°æ ºÎºñµ¿ ¼ö¼ú(FESS)Àº ¸¸¼º ºÎºñµ¿¿°, ºñ¿ëÁ¾ ¹× ±âŸ ºÎºñµ¿ º´º¯À» Ä¡·áÇϴ ǥÁØ Ä¡·á¹ýÀ¸·Î ºü¸£°Ô °¢±¤¹Þ°í ÀÖÀ¸¸ç, ±âÁ¸ÀÇ Ä§½ÀÀûÀÎ ¹æ¹ýÀ» ´ëüÇÏ´Â ÃÖ¼Ò Ä§½ÀÀûÀ̰í Á¤¹ÐÇÑ ±â¼ú·Î °¢±¤¹Þ°í ÀÖ½À´Ï´Ù. ºñ°­ÀÇ È¯±â¿Í ¹è¾×À» Á¤»óÀ¸·Î µÇµ¹¸± ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù. °íÇØ»óµµ ³»½Ã°æ°ú ¹Ì¼¼±â±¸¸¦ »ç¿ëÇÏ¿© Ä౸¸ÛÀ» ÅëÇØ ºÎºñµ¿¿¡ Á¢±ÙÇϹǷΠ¿ÜºÎ¿¡¼­ Àý°³ÇÒ Çʿ䰡 Å©°Ô ÁÙ¾îµé¾î ȸº¹ÀÌ »¡¶óÁý´Ï´Ù. À̺ñÀÎÈİú Àü¹®ÀǵéÀº ¼ö¼ú ÈÄ ÇÕº´Áõ °¨¼Ò, ÀÔ¿ø ±â°£ ´ÜÃà, Àå±âÀûÀÎ Ä¡·á ¼ºÀû Çâ»óÀ¸·Î ÀÎÇØ FESS¸¦ ¼±È£Çϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼­ ¸¸¼º ºÎºñµ¿¿°ÀÇ À¯º´·ü Áõ°¡´Â °øÇØ, ¾Ë·¹¸£±â, µµ½Ã »ýȰ½À°ü, ³»¼º±Õ °¨¿° µî¿¡ ±âÀÎÇϸç ȯÀÚÃþÀº È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¼ö¼ú ³»ºñ°ÔÀ̼Ç, ½Ç½Ã°£ ¿µ»ó, 3D ³»½Ã°æ ½Ã°¢È­ µîÀÇ ±â¼ú ¹ßÀüÀ¸·Î FESS´Â ±× ¾î´À ¶§º¸´Ù ¾ÈÀüÇϰí Á¤È®ÇØÁ³½À´Ï´Ù. ´õ ¸¹Àº ȯÀÚµéÀÌ º¸´Ù ÃÖ¼Òħ½ÀÀûÀ̰í ȸº¹ÀÌ ºü¸¥ ¼Ö·ç¼ÇÀ» ¿øÇϰí, ÁöºÒÀÚ°¡ °¡Ä¡ ±â¹Ý Ä¡·á¸¦ ¼±È£ÇÔ¿¡ µû¶ó FESS´Â Àü¹®ÀÇÀÇ ¼±Åÿ¡¼­ °ø°ø ¹× ¹Î°£ ÀÇ·á ½Ã½ºÅÛÀÇ À̺ñÀÎÈİú¿¡¼­ ³Î¸® äÅõǴ ¼ö¼ú Ç¥ÁØÀ¸·Î ÁøÈ­Çϰí ÀÖ½À´Ï´Ù.

Åø¿Í ¿µ»óÀÇ Çõ½ÅÀº ¼ö¼úÀÇ Á¤È®µµ¸¦ ¾î¶»°Ô ³ôÀ̰í Àִ°¡?

FESSÀÇ ÁøÈ­´Â ¼ö¼ú ±â¼úÀÇ ¹ßÀü, ƯÈ÷ ¿µ»ó Áø´Ü, ³»ºñ°ÔÀÌ¼Ç ¹× ±â±¸ÀÇ ¼ÒÇüÈ­¿Í ¹ÐÁ¢ÇÑ °ü·ÃÀÌ ÀÖ½À´Ï´Ù. ¿µ»ó À¯µµ ¼ö¼ú(IGS) ½Ã½ºÅÛÀº ÇöÀç ¼ö¼ú Àü CT ¹× MRI ½ºÄµÀ» ÅëÇØ ½Ç½Ã°£ Ž»öÀ» °¡´ÉÇϰÔÇÏ¿© ¾È¿Í ¹× ³ú¿Í °°Àº ÀÎÁ¢ ±¸Á¶¹°ÀÇ ¼Õ»ó À§ÇèÀ» Å©°Ô ÁÙ¿´À¸¸ç, 4K ¹× 3D ½Ã°¢È­ ±â´ÉÀ» °®Ãá °í±Þ ³»½Ã°æÀº ºñ±³ÇÒ ¼ö¾ø´Â ¼±¸íµµ¿Í ±íÀ̰¨À» Á¦°øÇÏ¿© ¿Ü°ú ÀÇ»çÀÇ Á¼Àº ÇØºÎÇÐÀû °æ·Î¸¦ Á¶ÀÛ ÇÒ ¼öÀÖ´Â ´É·ÂÀ» Çâ»ó½Ãŵ´Ï´Ù. ¿Ü°úÀÇ»çÀÇ Á¼Àº ÇØºÎÇÐÀû °æ·Î¿¡¼­ÀÇ ¼ö¼ú ´É·ÂÀ» Çâ»ó½Ãŵ´Ï´Ù. ¸¶ÀÌÅ©·Î µðºê¸®´õ ¹× °íÁÖÆÄ ÇÁ·Îºê¿Í °°Àº Àü±â±â±¸´Â Á¶Á÷ ¼±ÅÃÀû ÀýÁ¦¼ú¿¡ ÃÖÀûÈ­µÇ¾î ÀÖÀ¸¸ç, ÃÖ¼ÒÇÑÀÇ ¿Ü»óÀ¸·Î ¿°Áõ ¹× ¸·Èù Á¶Á÷À» º¸´Ù Á¦¾îµÈ ¹æ½ÄÀ¸·Î Á¦°ÅÇÒ ¼ö ÀÖ½À´Ï´Ù. dz¼± ºÎºñµ¿ ¼ºÇü¼úÀº Á¾Á¾ FESSÀÇ º¸¿ÏÀû ¶Ç´Â ¼±ÇàÀû Ä¡·á¹ýÀ¸·Î ¿©°ÜÁöÁö¸¸, °æ¹ÌÇÑ °æ¿ì ¼ö¼ú½ÇÀÇ ºÎ´ãÀ» ÁÙ¿©ÁÖ´Â Áø·á½Ç ±â¹ÝÀÇ ºñħ½ÀÀû Ä¡·á¹ýÀ¸·Î ³Î¸® º¸±ÞµÇ°í ÀÖ½À´Ï´Ù. ÁöÇ÷Àç, »ýüÈí¼ö¼º ½ºÅÙÆ®, ¼ö¼ú ÈÄ ¾àÁ¦¿ëÃ⼺ ÀÓÇöõÆ® µîÀÇ ±â¼ú Çõ½ÅÀº ¼ö¼ú ÈÄ Ä¡À¯¸¦ °³¼±Çϰí Àç¼ö¼ú·üÀ» ³·Ãß°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÇØºÎÇÐÀûÀ¸·Î º¹ÀâÇÑ ÄÉÀ̽º³ª Àç¼ö¼ú ÄÉÀ̽º¿¡¼­ °íÁ¤¹ÐµµÀÇ ½Ã¼úÀ» À§ÇØ ·Îº¿À» ÀÌ¿ëÇÑ º¸Á¶°¡ °ËÅäµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀû ºñ¾àÀû ¹ßÀüÀ¸·Î FESS´Â º¸´Ù ¿¹Ãø °¡´ÉÇϰí ÀçÇö¼ºÀÌ ³ô¾ÆÁ® ´Ù¾çÇÑ º´¿ø ¹× ¿Ü·¡ Ä¡·á ÇöÀå¿¡¼­ ½±°Ô »ç¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

¾î¶² ȯÀÚÃþ°ú ÀÓ»ó µ¿ÇâÀÌ ¼ö¿ä¸¦ °ßÀÎÇϰí Àִ°¡?

FESS¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ȯÀÚÃþ°ú ÀÓ»ó Ä¡·á ¸ðµ¨ÀÇ º¯È­¿¡ Å©°Ô ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¸¸¼º ºÎºñµ¿¿°Àº Àü ¼¼°è Àα¸ÀÇ 10% ÀÌ»óÀÌ ¾Î°í ÀÖÀ¸¸ç, »îÀÇ Áú, ¾÷¹« »ý»ê¼º, ÀÇ·á ºñ¿ë¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡´Â ÁúȯÀ¸·Î Àνĵǰí ÀÖ½À´Ï´Ù. ¹ßº´·üÀÌ °¡Àå ³ôÀº ¿¬·É´ë´Â ÁßÀå³âÃþÀ̸ç, ƯÈ÷ ´ë±â¿À¿°°ú ¾Ë·¹¸£°Õ ³ëÃâÀÌ ¸¹Àº µµ½ÃÁö¿ª°ú »ê¾÷Áö¿ª¿¡ ¸¹ÀÌ ¹ß»ýÇÕ´Ï´Ù. ±×·¯³ª ¾ÈÀü¼º°ú ȸº¹ ÇÁ·ÎÆÄÀÏÀÌ °³¼±µÊ¿¡ µû¶ó ¼Ò¾Æ ¹× ³ë³âÃþ ȯÀڵ鵵 ³»½Ã°æÀû ¹æ¹ýÀ¸·Î Ä¡·á¹Þ´Â °æÇâÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¾Ë·¹¸£±â¼º ºñ¿°, õ½Ä, HIV ¹× ´ç´¢º´°ú °°Àº ¸é¿ª °áÇÌ Áúȯ Áõ°¡µµ ºÎºñµ¿ Áúȯ À¯º´·ü Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ºÎºñµ¿ ¼ö¼ú °æÇèÀÌ Àִ ȯÀÚµéÀº ¼º°ø·üÀÌ ³ô°í ÇÕº´ÁõÀÌ Àû¾î Àç¼ö¼úÀ» ¼±ÅÃÇÏ´Â °æ¿ì°¡ ¸¹¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÇ·á ÇÁ·Î¹ÙÀÌ´õ ÀÔÀå¿¡¼­´Â ¸ÅÃâ âÃâ °¡´É¼º, ´çÀÏ ¼ö¼ú¿¡ ´ëÇÑ È¯ÀÚ ¼±È£µµ, ¼ö¼ú Àü ½Ã°£ ´ÜÃà µîÀÇ ÀÌÀ¯·Î À̺ñÀÎÈİú Ŭ¸®´Ð°ú ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)°¡ FESS¸¦ Á¦°øÇÏ´Â °æ¿ì°¡ ¸¹¾ÆÁö°í ÀÖ½À´Ï´Ù. ´Â ÀÓ»óÀû ±ä±Þ¼º°ú Áõ»ó ¿ÏÈ­ °¡´É¼ºÀ¸·Î ÀÎÇØ ¿¹¾àÀÌ ºü¸£°Ô ȸº¹µÇ°í ÀÖ´Â ¼ö¼ú Áß ÇϳªÀÔ´Ï´Ù.

±â´É¼º ³»½Ã°æ ºÎºñµ¿ ¼ö¼ú ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµË´Ï´Ù.

±â´ÉÀû ³»½Ã°æ ºÎºñµ¿ ¼ö¼ú(FESS) ½ÃÀåÀÇ ¼ºÀåÀº ÀÓ»ó ¹ßÀü, ȯÀÚ ¼ö¿ä, ÀÇ·á ½Ã½ºÅÛÀÇ ¿ì¼±¼øÀ§¿Í °ü·ÃµÈ ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ù°, ¸¸¼º ºñºÎºñµ¿¿°, ºñÆó»ö, ¾Ë·¹¸£±â¼º ¿ëÁ¾Áõ Áø´ÜÀÌ Áõ°¡ÇÏ¿© ¼ö¼ú ´ë»óÀÚ°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù. µÑ°, ¿µ»ó Áø´Ü, ³»ºñ°ÔÀ̼Ç, Àüµ¿±â±¸ÀÇ ±â¼úÀû ¹ßÀüÀ¸·Î ÇÕº´ÁõÀ» ÃÖ¼ÒÈ­Çϸ鼭 ¼ö¼ú ¼º°ø·üÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¼Â°, ¿Ü·¡ ȯÀÚ ¹× ÃÖ¼Ò Ä§½À ¼ö¼úÀÇ È°¼ºÈ­·Î ÀÎÇØ ÀÇ·á ±â°üÀÌ ±âÁ¸ Á¢±Ù¹ýº¸´Ù FESS¸¦ ¿ì¼±½ÃÇÏ´Â °æÇâÀÌ ÀÖ½À´Ï´Ù. ³Ý°, À¯¸®ÇÑ »óȯ Á¤Ã¥°ú ÃÑ Ä¡·áºñ Àý°¨Àº ÀÇ·á ÇÁ·Î¹ÙÀÌ´õ¿Í ÁöºÒÀÚ ¸ðµÎ¿¡°Ô FESS¸¦ ´õ¿í ¸Å·ÂÀûÀ¸·Î ¸¸µé°í ÀÖ½À´Ï´Ù. ´Ù¼¸Â°, ºÎºñµ¿ °Ç°­ ¹× Ä¡·áµÇÁö ¾ÊÀº °¨¿°ÀÇ À§Çè¿¡ ´ëÇÑ Àü ¼¼°èÀûÀÎ ÀÎ½Ä °³¼± Ä·ÆäÀÎÀº ȯÀÚµéÀÌ Á¶±â¿¡ Àü¹®ÀÇÀÇ ÁøÂûÀ» ¹Þµµ·Ï À¯µµÇÏ¿© ¼ö¼ú ÀüȯÀ²À» ³ôÀ̰í ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î ¹øµé ¼ö¼ú ŰƮ, ¼ö¼ú ÈÄ °ü¸® Àåºñ, ºÎºñµ¿ Àü¿ë ÀÓÇöõÆ®ÀÇ ÃâÇöÀ¸·Î À̺ñÀÎÈİú ÀÇ»ç´Â FESSÀÇ ¿öÅ©Ç÷ο츦 °£¼ÒÈ­ÇÒ ¼ö ÀÖ°Ô µÇ¾úÀ¸¸ç, FESS´Â ÀÓ»óÀû ÇØ°áÃ¥ÀÏ »Ó¸¸ ¾Æ´Ï¶ó Çö´ë À̺ñÀÎÈİú¿¡¼­ ¼ö¼ú È¿À²¼ºÀÌ ³ôÀº Ä¡·á¹ýÀ¸·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù.

ºÎ¹®

½Ã¼ú(»ó¾Ç ½Ã¼ú, »ç°ñ ½Ã¼ú); ÀûÀÀÁõ(¸¸¼º ºÎºñµ¿¿° ÀûÀÀÁõ, ÄÚÆú¸³Áõ ÀûÀÀÁõ); ÃÖÁ¾ »ç¿ë(º´¿ø ÃÖÁ¾ »ç¿ë, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ ÃÖÁ¾ »ç¿ë, Àü¹® Ŭ¸®´Ð ÃÖÁ¾ »ç¿ë)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÁÖ¸ñ 32»ç)

AI ÅëÇÕ

¿ì¸®´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Functional Endoscopic Sinus Surgery Market to Reach US$1.8 Billion by 2030

The global market for Functional Endoscopic Sinus Surgery estimated at US$1.2 Billion in the year 2024, is expected to reach US$1.8 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Maxillary Procedure, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Ethmoid Procedure segment is estimated at 7.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$339.0 Million While China is Forecast to Grow at 9.2% CAGR

The Functional Endoscopic Sinus Surgery market in the U.S. is estimated at US$339.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$353.7 Million by the year 2030 trailing a CAGR of 9.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.0% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global "Functional Endoscopic Sinus Surgery (FESS)" Market - Key Trends & Drivers Summarized

Why Is FESS Becoming the Preferred Approach for Chronic Sinus Conditions?

Functional Endoscopic Sinus Surgery (FESS) has rapidly gained prominence as the standard of care for treating chronic rhinosinusitis, nasal polyps, and other sinus pathologies, replacing traditional invasive methods with a minimally invasive, precision-based technique. The popularity of FESS stems from its ability to restore normal sinus ventilation and drainage without damaging healthy tissues. It employs high-definition endoscopes and micro-instruments to access sinus cavities through the nostrils, significantly reducing the need for external incisions and promoting faster recovery. ENT specialists prefer FESS due to reduced postoperative complications, shorter hospital stays, and better long-term outcomes. The rising incidence of chronic sinusitis globally-driven by pollution, allergies, urban lifestyles, and resistant bacterial infections-has expanded the patient base. Technological advances in surgical navigation, real-time imaging, and 3D endoscopic visualization have made FESS safer and more accurate than ever before. As more patients demand less invasive solutions with faster recovery times, and as payers lean toward value-based care, FESS is evolving from a specialist option to a widely adopted surgical norm in otolaryngology departments across both public and private healthcare systems.

How Are Innovations in Tools and Imaging Enhancing Surgical Precision?

The evolution of FESS is deeply tied to the progress of surgical technology, particularly in imaging, navigation, and instrument miniaturization. Image-guided surgery (IGS) systems now allow real-time navigation using preoperative CT or MRI scans, significantly reducing the risk of damaging adjacent structures such as the orbit or brain. Advanced endoscopes with 4K and 3D visualization offer unparalleled clarity and depth perception, enhancing surgeons’ ability to maneuver in narrow anatomical pathways. Powered instruments like microdebriders and radiofrequency probes are being optimized for tissue-selective resection, allowing more controlled removal of inflamed or obstructive tissue with minimal trauma. Balloon sinuplasty-often considered a complement or precursor to FESS-is also gaining traction for milder cases, offering office-based, non-invasive alternatives that reduce the burden on operating rooms. Innovations in hemostatic materials, bioabsorbable stents, and post-op drug-eluting implants are improving postoperative healing and reducing revision rates. Additionally, robotic assistance is being explored for high-precision procedures in anatomically complex or revision cases. These technological breakthroughs are making FESS more predictable, reproducible, and accessible across a range of hospital and ambulatory care settings.

Which Patient Demographics and Clinical Trends Are Driving Demand?

The growing demand for FESS is largely influenced by shifting patient demographics and clinical care models. Chronic sinusitis affects over 10% of the global population and is increasingly recognized as a condition that significantly impacts quality of life, work productivity, and healthcare costs. The highest incidence is seen in middle-aged adults, particularly in urban and industrial regions with high air pollution and allergen exposure. However, there’s a growing trend of pediatric and geriatric patients being treated via endoscopic methods as safety and recovery profiles improve. The global rise in allergic rhinitis, asthma, and immunocompromised conditions such as HIV and diabetes has also contributed to increased sinus disease prevalence. Patients with prior sinus surgeries are now more frequently opting for revision FESS due to better success rates and low complication profiles. From a provider standpoint, ENT clinics and outpatient surgical centers are increasingly offering FESS due to its revenue-generating potential, patient preference for day surgeries, and shorter preoperative timelines. As elective surgery volumes recover post-COVID, FESS is among the procedures seeing rapid scheduling rebounds due to its clinical urgency and symptom relief potential.

The Growth in the Functional Endoscopic Sinus Surgery Market Is Driven by Several Factors

The growth in the functional endoscopic sinus surgery (FESS) market is driven by several factors related to clinical advancements, patient demand, and health system priorities. First, increased diagnosis of chronic rhinosinusitis, nasal obstructions, and allergic polyposis is expanding the eligible surgical population. Second, technological progress in imaging, navigation, and powered instrumentation is enhancing procedure success rates while minimizing complications. Third, the push for outpatient and minimally invasive procedures is encouraging healthcare facilities to prioritize FESS over conventional approaches. Fourth, favorable reimbursement policies and reduced total cost of care are making it more appealing to providers and payers alike. Fifth, global awareness campaigns around sinus health and the risks of untreated infections are pushing patients to seek specialist consultations earlier, increasing procedural conversion rates. Finally, the emergence of bundled surgical kits, post-op care devices, and sinus-specific implantables is enabling ENT surgeons to streamline FESS workflows-making it not just a clinical solution, but also an operationally efficient offering within modern otolaryngology.

SCOPE OF STUDY:

The report analyzes the Functional Endoscopic Sinus Surgery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Procedure (Maxillary Procedure, Ethmoid Procedure); Indication (Chronic Sinusitis Indication, Nasal Polyposis Indication); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â